ArticleDiagnostic and interventional radiology (Ankara, Turkey)2021
MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up.
Article in Diagnostic and interventional radiology (Ankara, Turkey), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01377753 (MR Image Guided Focal Therapy in Prostate Cancer), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MR Image Guided Focal Therapy in Prostate Cancer
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy - a comprehensive review.Prostate cancer and prostatic diseases · 2026Review
- Transperineal Focal Laser Ablation of the Prostate for Prostate Cancer: A Systematic Review of the Literature.Cancers · 2025Review
- Focal therapy for prostate cancer.Abdominal radiology (New York) · 2025Review
- Percutaneous Magnetic Resonance Imaging-Guided Focal Laser Ablation (MRI-FLA) of Prostate Tumors: A Systematic Review and Network Meta-Analysis.Journal of personalized medicine · 2024Review
- Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care.Abdominal radiology (New York) · 2024Review
- Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project.Asian journal of urology · 2024Article
- The State-of-the-Art and Perspectives of Laser Ablation for Tumor Treatment.Cyborg and bionic systems (Washington, D.C.) · 2024Article
- The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Review
- A Pilot Study of DynamicMolecular imaging and biology · 2022Article
- Minimally invasive magnetic resonance image-guided prostate interventions.The British journal of radiology · 2022Review
- MR Imaging in Real Time Guiding of Therapies in Prostate Cancer.Life (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeWe aimed to assess post-interventional and 36-month follow-up results of a single-center, single-arm, in-bore phase I trial of focal laser ablation (FLA) guided by multiparametric magnetic resonance imaging (mpMRI).
methodsFLA procedures were done in-bore MRI using a transperineal approach. Primary endpoints were feasibility and safety expressed as lack of grade 3 complications. Secondary endpoints were changes in international prostate symptom score (IPSS), sexual health inventory for men (SHIM), quality of life (QoL) scores, and serum prostate specific antigen (PSA) levels. Treatment outcomes were assessed by combined mpMRI-ultrasound fusion-guided and extended sextant systematic biopsy after 12, 24, and optionally after 36 months.
resultsFifteen participants were included. Seven patients (46.67%) had Gleason 3+3 and 8 patients (53.33%) had Gleason 3+4 cancer. All patients tolerated the procedure well, and no grade 3/4 complications occurred. All grade 1 and 2 complications were transient and resolved completely. There was no significant change in mean IPSS from baseline (-1, p = 0.460) and QoL (0, p = 0.441) scores following FLA but there was a significant drop in mean SHIM scores (-2, p = 0.010) compared to pretreatment baselines. Mean PSA significantly decreased after FLA (-2.5, p < 0.001). Seven out of 15 patients (46.67%) had residual cancer in, adjacent, or in close proximity to the treatment area (1 × 4+3=7, 1 × 3+4=7, and 5 × 3+3=6). Four out of 15 patients (26.67%) underwent salvage therapy (2 repeat FLA, 2 radical prostatectomy).
conclusionAfter 3 years of follow-up we conclude focal laser ablation is safe and feasible without significant complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.